In this project, we want to work with community partners to develop a curriculum for developing and teaching racial literacy. The content will recognize the legacies of racism and draw on the rich community-based experiences of the Tar Heel Bus Tour.

The purpose of this study is to learn if a study medication called semaglutide (known as Ozempic) improves blood sugar control in people treated with dialysis.

The purpose of the study is to understand the experiences and needs of girls who have early puberty to improve their care.

Have you been diagnosed with pleural fluid, and have been referred for a pleural fluid drainage? If so, you may be able to participate in a research registry to help us learn more about lung cancer.

The purpose of this study is to understand how monitoring symptoms at home after lung cancer diagnosis could impact quality of care and the likelihood of returning to the hospital. This study will also help us understand whether symptom monitoring in patients with advanced lung cancer is helpful for patients and the clinical teams who care for them.

The purpose of this study is to use an MRI and other devices to observe the brain and body activity that happens when people feel certain emotions.

Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Purpose: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? Treatment with T-DM1 and placebo or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. If the breast cancer returns while on the study, the treatment will be changed. After completion of T-DM1 and/or placebo, or T-DM1 and tucatinib, the study doctor will continue to follow the patients condition with clinic visits every 6 months for 10 years and watch for side effects and for signs of breast cancer returning.

The purpose of this study is to evaluate a new treatment routine for patients with metastatic HER2 -positive breast cancer. We want to find out what effects, good and bad, using a Poly (ADP-Ribose) polymerase (PARP) inhibitor called niraparib in combination with trastuzumab has on patients with metastatic HER2- positive breast cancer.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.